Repligen (RGEN) news
Recent news
Repligen to provide addl details on deal impact in 3Q call
Repligen Corporation (NASDAQ:RGEN) reported third-quarter 2025 results that exceeded analyst expectations, with revenue rising 21.9% year-over-year to $188.8 million, compared to an estimated $181.9 million. The company also delivered a non-GAAP EPS of $0.46 , surpassing the $0.42 consensus…
AInvest Wire · Oct 6, 2026Repligen completes acquisition of Biolife Solutions
AInvest Wire · Oct 6, 2026Repligen Corporation: HSBC raises target price to $210 from $170
HSBC Holdings PLC has raised its price target for Repligen Corporation (NASDAQ: RGEN) to $210 from $170, signaling increased confidence in the biotechnology company’s stock performance. This adjustment aligns with recent positive developments, including strong quarterly earnings and growing…
AInvest Wire · Sep 1, 2026Repligen raises FY adjusted EPS to $2.03-$2.09
AInvest Wire · Jul 28, 2026Repligen raises FY26 organic revenue growth guidance to 10.5%-13.5%
Repligen Corp. has raised its full-year 2026 organic revenue growth guidance to a range of 10.5% to 13.5%, reflecting stronger-than-expected performance across its core businesses. The updated guidance comes amid continued demand for its products in the biopharmaceutical and cell and gene therapy…
AInvest Wire · Jul 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.